|
|
 Previous Article | Table of Contents | Next Article 
Removal of T cells from bone marrow for transplantation: a monoclonal
antilymphocyte antibody that fixes human complement
G Hale, S Bright, G Chumbley, T Hoang, D Metcalf, AJ Munro and H Waldmann
Graft-versus-host disease is one of the major problems in clinical bone
marrow transplantation. Many experiments in animals have shown that it
could be greatly reduced if mature T lymphocytes were removed from the
donor marrow. Here we describe a new rat monoclonal antibody, CAMPATH 1,
which is suitable for depleting lymphocytes from human marrow grafts.
CAMPATH 1 is an IgM that fixes human complement. It binds to both T and B
lymphocytes and some monocytes but not to other hemopoietic cells. When
peripheral blood mononuclear cells were treated with CAMPATH 1 and
complement, more than 99% of lymphocytes were killed and viable T cells
could no longer be detected. Under these conditions, in vitro
multipotential erythroid and myeloid colony-forming cells were unaffected.
As well as being used for in vitro treatment of bone marrow to remove T
cells, CAMPATH 1 could potentially be applied to other experimental and
clinical situations where depletion of lymphoid cells is required,
including serotherapy to achieve immunosuppression for organ transplants or
to treat lymphocytic leukemias.
Volume 62,
Issue 4,
pp. 873-882,
10/01/1983
Copyright © 1983 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Lapalombella, X. Zhao, G. Triantafillou, B. Yu, Y. Jin, G. Lozanski, C. Cheney, N. Heerema, D. Jarjoura, A. Lehman, et al.
A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
Clin. Cancer Res.,
January 15, 2008;
14(2):
569 - 578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S. Lin, I. W. Flinn, R. Modali, T. A. Lehman, J. Webb, S. Waymer, M. E. Moran, M. S. Lucas, S. S. Farag, and J. C. Byrd
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
Blood,
January 1, 2005;
105(1):
289 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, S. Stilgenbauer, and I. W. Flinn
Chronic Lymphocytic Leukemia
Hematology,
January 1, 2004;
2004(1):
163 - 183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, T. K. Kimlinger, J. A. Lust, K. Donovan, and T. E. Witzig
Expression of CD52 on plasma cells in plasma cell proliferative disorders
Blood,
August 1, 2003;
102(3):
1075 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Morris, P. Rebello, K. J. Thomson, K. S. Peggs, C. Kyriakou, A. H. Goldstone, S. Mackinnon, and G. Hale
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
Blood,
July 1, 2003;
102(1):
404 - 406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. S. Buggins, G. J. Mufti, J. Salisbury, J. Codd, N. Westwood, M. Arno, K. Fishlock, A. Pagliuca, and S. Devereux
Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab
Blood,
August 13, 2002;
100(5):
1715 - 1720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Klangsinsirikul, G. I. Carter, J. L. Byrne, G. Hale, and N. H. Russell
Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution
Blood,
April 1, 2002;
99(7):
2586 - 2591.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Degousee, F. Ghomashchi, E. Stefanski, A. Singer, B. P. Smart, N. Borregaard, R. Reithmeier, T. F. Lindsay, C. Lichtenberger, W. Reinisch, et al.
Groups IV, V, and X Phospholipases A2s in Human Neutrophils. ROLE IN EICOSANOID PRODUCTION AND GRAM-NEGATIVE BACTERIAL PHOSPHOLIPID HYDROLYSIS
J. Biol. Chem.,
February 8, 2002;
277(7):
5061 - 5073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Isaacs
From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies
Rheumatology,
July 1, 2001;
40(7):
724 - 738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Hederer, C. Guntermann, N. Miller, P. Nagy, J. Szollosi, S. Damjanovich, G. Hale, and D. R. Alexander
The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells
Int. Immunol.,
April 1, 2000;
12(4):
505 - 516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Focarelli, S. Francavilla, F. Francavilla, C. D. Giovampaola, A. Santucci, and F. Rosati
A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa
Mol. Hum. Reprod.,
January 1, 1999;
5(1):
46 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hale, M.-J. Zhang, D. Bunjes, H. G. Prentice, D. Spence, M. M. Horowitz, A. J. Barrett, and H. Waldmann
Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection
Blood,
December 15, 1998;
92(12):
4581 - 4590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Peters, E. G. Shapiro, J. Anderson, P. J. Henslee-Downey, M. R. Klemperer, M. J. Cowan, E. F. Saunders, P. A. deAlarcon, C. Twist, J. B. Nachman, et al.
Hurler Syndrome: II. Outcome of HLA-Genotypically Identical Sibling and HLA-Haploidentical Related Donor Bone Marrow Transplantation in Fifty-Four Children
Blood,
April 1, 1998;
91(7):
2601 - 2608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Treumann, M. R. Lifely, P. Schneider, and M. A. J. Ferguson
Primary Structure of CD52
J. Biol. Chem.,
March 17, 1995;
270(11):
6088 - 6099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sieff, S. Emerson, R. Donahue, D. Nathan, E. Wang, G. Wong, and S. Clark
Human recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin
Science,
December 6, 1985;
230(4730):
1171 - 1173.
[Abstract]
[PDF]
|
|
|
|
|
